Healthcare is one of the largest sources of “big data,” accounting for upwards of 30% of all data produced globally.1 Early on, the potential benefits of this data for healthcare outcomes were immediately evident. As that promise has begun to materialize, with the advent of AI and machine learning, real signals of improvement in therapeutic… The post Early-phase study design considerations for long-term follow-up in vaccine clinical trials appeared first on Drug Discovery and Development.| Drug Discovery and Development
Boston, 23rd July 2025: The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, is launching two complementary initiatives to transform pharmacovigilance (PV) in response to growing member demand. A new dedicated AI in Safety & PV Community of Experts (CoE) will explore how to apply AI safely, ethically and effectively within pharmacovigilance workflows.| Pistoia Alliance